AURA BIOPHARM RECEIVES A LETTER OF INTENT FROM KEDRION BIOPHARMA FOR THE DEVELOPMENT OF AUR-1001 IN APS
Kedrion biopharma signed a letter of intent (LOI) to express its interest to participate in the development of AUR-1001 for the treatement of antiphospholipid syndrome. AUR-1101 is an anti Beta2 GP1 monoclonal antibody which represents a first-in-class treatment for antiphospolipid syndrome (Hughes syndrome), an autoimmune disease with multiple clinical manifestations, highly invalidating and deadly and with no specific available treatment. AUR-1001 is the lead program of AURA Biopharm and is available for licensing and co-development.
Aura Biopharm is a company that looks for new licensing opportunities of molecules with potential therapeutic activity in a variety of diseases such as autoimmune and orphan diseases with unmet medical needs. These in-licensing molecules are then partly developed by the company preferably in collaboration with other partners and then out-licensed to larger biothec/pharmaceutical companies to complete their development program. Recently founded AURA Biopharm is developing a treatment for a serious rare autoimmune disease, Antiphospholipid Syndrome. Based in Oslo, but operating virtually and led by an International team of very experienced scientists, managers and experts, AURA Biopharm has developed an exciting collaborative business model with great possibilities to deliver future breakthrough therapies to the market.
Kedrion Biopharma is a company that focuses on the isolation, processing and commercialization of plasma derivatives for treatment of a variety of medical conditions. The company has an interest in the area of orphan drug development and has recently established a laboratory for reaserach into plasma-derived orphan drug.